CompletedPhase 1NCT02101073

ALX-0061 Phase I Bioavailability Study in Healthy Volunteers

Studying NON RARE IN EUROPE: Rheumatoid arthritis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Ablynx, a Sanofi company
Principal Investigator
Steven De Bruyn, MD
Ablynx NV
Intervention
ALX-0061(biological)
Enrollment
70 target
Eligibility
18-55 years · All sexes
Timeline
20142014

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02101073 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Rheumatoid arthritis

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Rheumatoid arthritis

← Back to all trials